GeoVax Reports First Quarter 2026 Financial Results and Details GEO-MVA Phase 3 Trial Plans Amid Strategic Shift

GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the quarter ended March 31, 2026, highlighting progress on its lead vaccine candidate GEO-MVA and a strategic refocus on its immuno-oncology platform Gedeptin. The company reported a net loss of $5.3 million, compared to $5.4 million in the same period last year, driven by reduced research and development expenses after the termination of a BARDA contract for its COVID-19 vaccine program.

GeoVax is advancing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for mpox and smallpox, under an expedited regulatory pathway aligned with the European Medicines Agency (EMA). The company plans to initiate a pivotal Phase 3 immunobridging study expected to enroll approximately 500 participants. The study aims to demonstrate non-inferiority of neutralizing antibody responses compared to an approved MVA comparator vaccine. According to David A. Dodd, Chairman and CEO, the company believes GEO-MVA is uniquely positioned at the intersection of global public health preparedness, biodefense resiliency, and domestic manufacturing priorities. The program has completed cGMP clinical trial material production and fill/finish activities, and has selected a CRO for trial execution.

In parallel, GeoVax is strengthening its immuno-oncology positioning with Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform. The company recently entered into an exclusive license agreement with Emory University covering intellectual property for combining Gedeptin with immune checkpoint inhibitors. GeoVax believes Gedeptin’s localized tumor-targeting mechanism can convert immunologically “cold” tumors into responsive microenvironments, potentially enhancing PD-1-based therapies. The company plans to pursue combination strategies in head and neck cancer, including neoadjuvant and first-line settings.

Financially, GeoVax reported cash balances of $1.3 million as of March 31, 2026, down from $3.1 million at year-end 2025. Research and development expenses decreased to $3.9 million from $5.4 million, primarily due to the discontinuation of BARDA-related activities and reduced spending on the GEO-CM04S1 COVID-19 program. General and administrative expenses declined to $1.4 million from $1.7 million, reflecting lower investor relations and stock-based compensation costs. The company recognized no government contract revenue in the first quarter of 2026, compared to $1.6 million in the prior-year period from the BARDA Project NextGen award, which was terminated in April 2025.

GeoVax’s strategic prioritization focuses on GEO-MVA due to its established MVA platform validation, expedited regulatory alignment, and growing demand for diversified orthopoxvirus vaccine supply. The company also sees long-term optionality in Gedeptin within the evolving checkpoint inhibitor landscape. For more information, visit www.geovax.com.